BRPI0512040A - composição farmacêutica, método de modificação de receptores de célula de tumor, método de aperfeiçoar seletividade alvo de anticorpos, método de tratar cáncer, kit, uso de prolina - Google Patents
composição farmacêutica, método de modificação de receptores de célula de tumor, método de aperfeiçoar seletividade alvo de anticorpos, método de tratar cáncer, kit, uso de prolinaInfo
- Publication number
- BRPI0512040A BRPI0512040A BRPI0512040-3A BRPI0512040A BRPI0512040A BR PI0512040 A BRPI0512040 A BR PI0512040A BR PI0512040 A BRPI0512040 A BR PI0512040A BR PI0512040 A BRPI0512040 A BR PI0512040A
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- proline
- treating cancer
- kit
- tumor cell
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 230000002708 enhancing effect Effects 0.000 title 1
- 238000002715 modification method Methods 0.000 title 1
- 210000004881 tumor cell Anatomy 0.000 title 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 150000003147 proline derivatives Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
COMPOSIçãO FARMACêUTICA, MéTODO DE MODIFICAçãO DE RECEPTORES DE CéLULA DE TUMOR, MéTODO DE APERFEIçOAR SELETIVIDADE ALVO DE ANTICORPOS, MéTODO DE TRATAR CANCER, KIT, USO DE PROLINA A presente invenção refere-se a uma composição farmacêutica compreendendo prolina ou derivados de prolina ou seus sais, ésteres, isómeros, racematos, enanciómeros ou pró-drogas em conjunto com um ligante anticâncer, preferivelmente um anticorpo dirigido a um antigeno de tumor. A invenção também á dirigida ao uso de prolina ou derivados de prolina ou seus sais, ásteres, isómeros ou pró-drogas para a fabricação de uma composição farmacêutica para tratar câncer e a um método de tratamento de câncer mediante administração da composição.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57883204P | 2004-06-14 | 2004-06-14 | |
| PCT/EP2005/006184 WO2005120495A1 (en) | 2004-06-14 | 2005-06-07 | Anti-cancer composition comprising proline or its derivatives and an anti-tumour antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0512040A true BRPI0512040A (pt) | 2008-02-06 |
Family
ID=35064616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0512040-3A BRPI0512040A (pt) | 2004-06-14 | 2005-06-07 | composição farmacêutica, método de modificação de receptores de célula de tumor, método de aperfeiçoar seletividade alvo de anticorpos, método de tratar cáncer, kit, uso de prolina |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7727530B2 (pt) |
| EP (1) | EP1765328B1 (pt) |
| JP (1) | JP2008502622A (pt) |
| KR (1) | KR20070026646A (pt) |
| CN (1) | CN1997365A (pt) |
| AT (1) | ATE534386T1 (pt) |
| AU (1) | AU2005251463A1 (pt) |
| BR (1) | BRPI0512040A (pt) |
| CA (1) | CA2568306A1 (pt) |
| MX (1) | MXPA06014731A (pt) |
| RU (1) | RU2007101074A (pt) |
| WO (1) | WO2005120495A1 (pt) |
| ZA (1) | ZA200700367B (pt) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY138883A (en) * | 2000-08-29 | 2009-08-28 | Government Of Malaysia As Represented By The Ministry Of Science Tehnology And Innovation Malaysia | Use of asiatic acid for treatment of cencer |
| JP2005518453A (ja) | 2002-02-25 | 2005-06-23 | ディフュージョン・ファーマシューティカルズ・エルエルシー | 二極性トランスカロテノイド塩およびそれらの使用 |
| US7759506B2 (en) | 2002-02-25 | 2010-07-20 | Diffusion Pharmaceuticals Llc | Bipolar trans carotenoid salts and their uses |
| KR101315904B1 (ko) | 2005-02-24 | 2013-10-08 | 디퓨젼 파마슈티컬즈 엘엘씨 | 트랜스 카로티노이드, 이들의 합성, 제제화 및 용도 |
| EP2589588A1 (en) | 2007-04-13 | 2013-05-08 | Diffusion Pharmaceuticals Llc | Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease |
| CN101878040A (zh) | 2007-10-31 | 2010-11-03 | 扩散药品有限公司 | 一类促进小分子扩散的新型治疗剂 |
| US10130689B2 (en) | 2009-06-22 | 2018-11-20 | Diffusion Pharmaceuticals Llc | Diffusion enhancing compounds and their use alone or with thrombolytics |
| AU2011260390B2 (en) * | 2010-06-01 | 2016-11-24 | Ernst-Moritz-Arndt Universitat Greifswald | Means and methods for diagnosing pancreatic cancer in a subject |
| CN103124498A (zh) | 2010-06-02 | 2013-05-29 | 扩散药品有限公司 | 双极性反式类胡萝卜素的口服制剂 |
| EP3432929A4 (en) | 2016-03-24 | 2019-11-27 | Diffusion Pharmaceuticals LLC | USE OF BIPOLAR TRANSCAROTINOIDS WITH CHEMOTHERAPY AND RADIOTHERAPY FOR THE TREATMENT OF CANCER |
| KR102012554B1 (ko) * | 2016-07-13 | 2019-08-23 | 주식회사 노브메타파마 | 사이클로 히스티딘-프롤린을 유효성분으로 포함하는 세포 보호용 조성물 |
| CN114028388B (zh) * | 2021-12-16 | 2023-05-12 | 郑州大学第一附属医院 | 脯氨酸在制备肺癌治疗药物中的应用 |
| CN116092631A (zh) * | 2023-01-17 | 2023-05-09 | 湖南安泰康成生物科技有限公司 | 铁死亡诱导剂与电场联用的肿瘤治疗系统 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US6153643A (en) * | 1984-11-05 | 2000-11-28 | Hoerrmann; Wilhelm | Anti-cancer-substance |
| CA1281288C (en) * | 1984-11-05 | 1991-03-12 | Wilhelm Hoerrmann | Tumor therapy |
| US5665371A (en) * | 1985-05-20 | 1997-09-09 | Hoerrmann; Wilhelm | Medicines which contain derivatives of proline or hydroxyproline |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| US5837283A (en) * | 1997-03-12 | 1998-11-17 | The Regents Of The University Of California | Cationic lipid compositions targeting angiogenic endothelial cells |
| DE10359828A1 (de) * | 2003-12-12 | 2005-07-28 | Zoser B. Dr.Rer.Nat. Salama | CHP-Gemcitabin- Kombinationsmittel und ihre Verwendung als Antitumorwirkstoffe, insbesondere Antimetastasierungswirkstoffe |
| MXPA06007007A (es) * | 2003-12-18 | 2007-06-08 | Zoser B Salama | Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores. |
-
2005
- 2005-06-07 RU RU2007101074/15A patent/RU2007101074A/ru not_active Application Discontinuation
- 2005-06-07 EP EP05770217A patent/EP1765328B1/en not_active Expired - Lifetime
- 2005-06-07 AU AU2005251463A patent/AU2005251463A1/en not_active Abandoned
- 2005-06-07 JP JP2007515831A patent/JP2008502622A/ja not_active Withdrawn
- 2005-06-07 CN CNA2005800238112A patent/CN1997365A/zh active Pending
- 2005-06-07 CA CA002568306A patent/CA2568306A1/en not_active Abandoned
- 2005-06-07 AT AT05770217T patent/ATE534386T1/de active
- 2005-06-07 MX MXPA06014731A patent/MXPA06014731A/es not_active Application Discontinuation
- 2005-06-07 ZA ZA200700367A patent/ZA200700367B/en unknown
- 2005-06-07 KR KR1020067027243A patent/KR20070026646A/ko not_active Withdrawn
- 2005-06-07 BR BRPI0512040-3A patent/BRPI0512040A/pt not_active IP Right Cessation
- 2005-06-07 WO PCT/EP2005/006184 patent/WO2005120495A1/en not_active Ceased
- 2005-06-08 US US11/147,648 patent/US7727530B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008502622A (ja) | 2008-01-31 |
| EP1765328A1 (en) | 2007-03-28 |
| EP1765328B1 (en) | 2011-11-23 |
| US7727530B2 (en) | 2010-06-01 |
| WO2005120495A1 (en) | 2005-12-22 |
| CA2568306A1 (en) | 2005-12-22 |
| KR20070026646A (ko) | 2007-03-08 |
| MXPA06014731A (es) | 2007-04-25 |
| ZA200700367B (en) | 2008-07-30 |
| US20050276810A1 (en) | 2005-12-15 |
| AU2005251463A1 (en) | 2005-12-22 |
| RU2007101074A (ru) | 2008-07-20 |
| ATE534386T1 (de) | 2011-12-15 |
| CN1997365A (zh) | 2007-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY39024A (es) | Proteínas terapéuticas de unión a dll4 | |
| CY1121148T1 (el) | Παραγοντες συνδεσης vegf/dll4 και χρησεις αυτων | |
| EA201100779A1 (ru) | Композиции антител к cxcr1 и способы их применения | |
| IL311603B2 (en) | Bispecific antibodies and compounds containing them for cancer treatment | |
| EA201070618A1 (ru) | 4-пиразолил-n-арилпиримидин-2-амины и 4-пиразолил-n-гетероарилпиримидин-2-амины в качестве ингибиторов киназ janus | |
| EA202091514A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ РАКА ТОЛСТОЙ КИШКИ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ НАНОЧАСТИЦАМИ С ИНГИБИТОРОМ mTOR | |
| EA200970317A1 (ru) | Комбинированное лечение опухолей, экспрессирующих cd38 | |
| NO2017019I2 (no) | Enzalutamid eller et farmasøytisk akseptabelt salt derav | |
| CR9512A (es) | Metodos para el tratamiento de tumores de cerebro con anticuerpos | |
| SG170728A1 (en) | Anti-tumor cell antigen antibody therapeutics | |
| NZ704269A (en) | Rspo3 binding agents and uses thereof | |
| CY1115572T1 (el) | Αντι cxcr4 αντισωματα και χρηση αυτων για τη θεραπεια καρκινου | |
| EA201290062A1 (ru) | Соединения, связывающие белки теплового шока, композиции и способы получения указанных соединений | |
| BRPI0711908B8 (pt) | anticorpo anti-interleucina-18 humanizado, composição farmacêutica, uso de um anticorpo anti-interleucina 18, e, método de produção de um anticorpo. | |
| AR059922A1 (es) | Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos | |
| ATE534386T1 (de) | Antikrebs-zusammensetzung mit prolin bzw. prolinderivaten und einem antitumorantikörper | |
| BR112022010702A2 (pt) | Macrociclos para uso no tratamento de doenças | |
| BR112016023011A2 (pt) | tratamento de câncer gástrico | |
| ATE353650T1 (de) | Kombinationstherapie zur behandlung von krebs | |
| DE60331827D1 (de) | Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren | |
| AR073218A1 (es) | Anticuerpo antineuropilina 2 humano, induccion de la expresion del gen supresor de tumores p53 por la neutralizacion de la neuropilina 2 para el tratamiento de cancer | |
| WO2011045352A3 (en) | Spleen tyrosine kinase and brain cancers | |
| AR055072A1 (es) | Uso de anticuerpos anti- madcam para el tratamiento de enfermedad celiaca y esprue tropical | |
| EA200702136A1 (ru) | Композиции станнсопорфина и их применение | |
| BRPI0515115A (pt) | método de tratar uma doença de pele proliferativa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |